miR ‑144‑3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2.

miR‑144‑3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2. Oncol Rep. 2018 Oct 08;: Authors: Yin Y, Liu H, Xu J, Shi D, Zhai L, Liu B, Wang L, Liu G, Qin J Abstract Chemotherapeutic drug resistance is correlated with treatment failure and poor prognosis among lung cancer patients. Numerous studies indicate the relevance of miRNAs in inducing certain drug resistance. In the course of the study, we unexpectedly found that miR‑144‑3p could regulate the cisplatin resistance of lung cancer cells via Nrf2. However, Nrf2 also could reverse activate the expression of miR‑144‑3p by binding to the ARE box in the miR‑144‑3p promoter. This may be a self‑protection mechanism of the body. In addition, we also found that in other cancer cell lines, such as HepG2, miR‑144‑3p also had the function of regulating cisplatin resistance. These findings may provide some theoretical reference for the clinical inhibition of cisplatin resistance. PMID: 30542710 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research